Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability
Authors' conclusion
Although estimated and not measured, the exposure to oral semaglutide may provide outcome-dependent information. While the prescribed dose seems sufficient to predict glycaemic response, estimated exposure provides additional value for weight loss and GI tolerability.
Study context
- Population
- Patients with T2D initiating oral semaglutide; 31.6% women, mean age 65.6 yearsanalysed
- Participants
- 256 patients
- Exposure
- Prescribed dose vs estimated exposure as predictors of response
- Outcome
- Associations of dose and eC avg with changes in HbA1c and percent body weight, and GI side effects
Methodological detailsreal-world, population pharmacokinetic model-estimated exposure, mixed-effects models
- Real-world
- Population pharmacokinetic model-estimated exposure
- Mixed-effects models
Main finding
As reported in the abstract
Changes in HbA1c, body weight and GI side effects · median follow-up 19 months
- HbA1c decline
- 0.7%
- Body weight decline
- 7.5%
- Reported GI side effects
- 41.8%
- ΔHbA1c: dose model outperformed eC avg model
- p < 0.01
- Weight loss: eC avg showed modestly improved fit
- p < 0.001
Observational data: associations, not effects.
Safety
GI side effects · median follow-up 19 months
- Patients reporting GI side effects
- 41.8%
Original publication
Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability. Diabetes Obes Metab. Published 10 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →